Single Patient Protocol: A Phase II Study Using the Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated Neoantigens in a Patient With Metastatic Cancer Plus the Administration of Pembrolizumab

Expanded access No longer available National Institutes of Health Clinical Center (CC)

Single Patient Expanded Access

Evaluation	Drug	Modality	Dose	Route
Subject	Individual Patient TCR-Transduced PBL	Cell therapy	5e+10 cells	Intravenous
Subject	Pembrolizumab	Monoclonal antibody	2 mg/kg	Intravenous
Background	Cyclophosphamide	Other / unclassified	60 mg/kg	Intravenous
Background	Fludarabine	Small molecule	25 mg/m2	Intravenous
Background	aldesleukin	Protein / enzyme biologic	720000 iu/kg	Intravenous

No indication recorded.